Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 48: 673-675, 2002;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (26)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Müller-Bardorff, M.
Right arrow Articles by Katus, H. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Müller-Bardorff, M.
Right arrow Articles by Katus, H. A.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2002;48:673-675.)
© 2002 American Association for Clinical Chemistry, Inc.

Technical Briefs

Release Kinetics of Cardiac Troponin T in Survivors of Confirmed Severe Pulmonary Embolism

Margit Müller-Bardorff1, Britta Weidtmann1, Evangelos Giannitsis1, Volkhard Kurowski1 and Hugo A. Katus1a

1 Universitätsklinikum Lübeck, Medizinische Klinik II, Ratzeburger Allee 160, 23538 Lübeck, Germany

aauthor for correspondence: fax 49-451-5006437, e-mail katus@medinf.mu-luebeck.de)

Cardiac troponins may be increased in patients with confirmed pulmonary embolism (PE), even in the absence of significant coronary artery disease (CAD), and indicate increased risk for subsequent death (1). Cardiac troponin T (cTnT) correlates with the presence and degree of right-ventricular dysfunction (1)(2). In our recent study (1), 18 of 56 patients (32%) with PE had significant increases in cTnT. Eight of the nine patients with fatal outcome had increased cTnT. In the present study, we investigated all consecutive survivors of angiographically confirmed acute PE who developed cTnT >=0.1 µg/L to evaluate cTnT time release in PE and to provide a rationale for an optimal blood-sampling protocol to improve risk stratification.

The study was approved by the local ethics committee of the University of Luebeck. All patients gave informed consent.

We enrolled nine consecutive patients with confirmed PE developing cTnT concentrations >=0.1 µg/L, who survived the acute event and sampling period until normalization of cTnT concentrations. PE was suspected in the presence of an acute onset of symptoms such as dyspnea, pleuritic chest pain, syncope, hypotension, or shock and was confirmed by pulmonary angiography. The diagnostic work-up included transthoracic echocardiography, electrocardiography, blood-gas analysis, ventilation-perfusion scan, and coronary angiography. . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Respir. Crit. Care Med.Home page
M. Lankeit, T. Kempf, C. Dellas, M. Cuny, H. Tapken, T. Peter, M. Olschewski, S. Konstantinides, and K. C. Wollert
Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism
Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1018 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Puls, C. Dellas, M. Lankeit, M. Olschewski, L. Binder, A. Geibel, C. Reiner, K. Schafer, G. Hasenfuss, and S. Konstantinides
Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism
Eur. Heart J., January 2, 2007; 28(2): 224 - 229.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S. Korff, H. A Katus, and E. Giannitsis
Differential diagnosis of elevated troponins.
Heart, July 1, 2006; 92(7): 987 - 993.
[Full Text] [PDF]

Home page
 CMAJHome page
L. Babuin and A. S. Jaffe
Troponin: the biomarker of choice for the detection of cardiac injury
Can. Med. Assoc. J., November 8, 2005; 173(10): 1191 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Macrea, P. Pruszczyk, and A. Torbicki
Cardiac Troponin T Monitoring and Acute Pulmonary Embolism
Chest, August 1, 2004; 126(2): 655 - 656.
[Full Text] [PDF]

Home page
 HeartHome page
L La Vecchia, F Ottani, L Favero, G L Spadaro, A Rubboli, C Boanno, G Mezzena, A Fontanelli, and A S Jaffe
Increased cardiac troponin I on admission predicts in-hospital mortality in acute pulmonary embolism
Heart, June 1, 2004; 90(6): 633 - 637.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. Kucher and S. Z. Goldhaber
Cardiac Biomarkers for Risk Stratification of Patients With Acute Pulmonary Embolism
Circulation, November 4, 2003; 108(18): 2191 - 2194.
[Full Text] [PDF]

Home page
 CirculationHome page
C. W. Hamm, E. Giannitsis, and H. A. Katus
Cardiac Troponin Elevations in Patients Without Acute Coronary Syndrome
Circulation, December 3, 2002; 106(23): 2871 - 2872.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Association for Clinical Chemistry.